biomedicina slovenica

pr=Beslija : 5

1. Vrdoljak Eduard; Bodoky Gyorgy; Jassem Jacek; Popescu Razvan A.; Pirker Robert; Čufer Tanja; Beslija Semir; Eniu Alexsandru; Todorović Vladimir; Kopečková Katerina
   Expenditures on oncology drugs and cancer mortality-to-incidence ratio in Central and Eastern Europe
   2019 ►
2. Vrdoljak Eduard; Bodoky Gyorgy; Jassem Jacek; Popescu Razvan A.; Mardiak Jozef; Pirker Robert; Čufer Tanja; Beslija Semir; Eniu Alexsandru; Todorović Vladimir
   Cancer Control in Central and Eastern Europe
   2016 ►
3. Ciuleanu Tudor; Scheithauer W.; Kurteva G.; Ocvirk Janja; Koza I.; Papamichael D.; Wenczl M.; Brodowicz Thomas; Beslija Semir; Zielinski Christoph C.
   A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
   2008 ►
4. Brodowicz T; Beslija S; Červek J; Mršič-Krmpotič Z; Tchernozemsky I; Wiltschke C; Ghilezan N; Grgič M; Jassem J; Zielinski C
   Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluoro-uracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European cooperative oncology group (CECOG)
   2001 ►
5. Zielinski C; Beslija S; Červek J; Mrsič-Krmpotič Z; Tchernozemsky I; Witschke C; Ghilezan N; Grgič M; Jassem J; Tzekova V
   Gemcitabine/Epirubicin/Paclitaxel (GET) vs. 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase III trial of the central European cooperative oncology group (CECOG)
   2001 ►

New search      Comments      Top of page Institute for Biostatistics and Medical Informatics